Bevacizumab in the treatment of ovarian cancer

被引:31
|
作者
Han, Ernest S. [1 ]
Monk, Bradley J. [1 ]
机构
[1] Univ Calif Irvine, Div Gynecol Oncol, Chao Family Comprehen Canc Ctr, Orange, CA 92868 USA
关键词
antiangoigenesis; bevacizumab; ovarian cancer; VEGF;
D O I
10.1586/14737140.7.10.1339
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Current treatment for epithelial ovarian cancer involves a combination of surgery and chemotherapy with platinum- and taxane-based chemotherapy. With the recent approval of the anti-VEGF antibody bevacizumab by several regulatory bodies in colorectal and non-small-cell lung cancers, interest has developed regarding the potential role of bevacizumab therapy in ovarian cancer. Several case series and Phase II studies indicate that in ovarian cancer bevacizumab is active as a single agent or in combination with other drugs. Currently, ongoing Phase III trials are testing bevacizumab in front-line adjuvant therapy with carboplatin and paclitaxel. Bevacizumab has been generally well tolerated in ovarian cancer patients, but recent reports on increased risk of gastrointestinal perforations have gained attention. Bevacizumab offers a novel therapeutic modality in the treatment of epithelial ovarian cancers.
引用
收藏
页码:1339 / 1345
页数:7
相关论文
共 50 条
  • [1] Bevacizumab in the Treatment of Ovarian Cancer
    Florian Heitz
    Philipp Harter
    Jana Barinoff
    Bianca Beutel
    Paevi Kannisto
    Jacek P. Grabowski
    Julia Heitz
    Christian Kurzeder
    Andreas du Bois
    [J]. Advances in Therapy, 2012, 29 : 723 - 735
  • [2] Bevacizumab in the treatment of ovarian cancer
    Eskander, Ramez N.
    Randall, Leslie M.
    [J]. BIOLOGICS-TARGETS & THERAPY, 2011, 5 : 1 - 5
  • [3] Bevacizumab in the Treatment of Ovarian Cancer
    Heitz, Florian
    Harter, Philipp
    Barinoff, Jana
    Beutel, Bianca
    Kannisto, Paevi
    Grabowski, Jacek P.
    Heitz, Julia
    Kurzeder, Christian
    du Bois, Andreas
    [J]. ADVANCES IN THERAPY, 2012, 29 (09) : 723 - 735
  • [4] The roles and limitations of bevacizumab in the treatment of ovarian cancer
    Hidekatsu Nakai
    Noriomi Matsumura
    [J]. International Journal of Clinical Oncology, 2022, 27 : 1120 - 1126
  • [5] Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
    Burger, Robert A.
    Brady, Mark F.
    Bookman, Michael A.
    Fleming, Gini F.
    Monk, Bradley J.
    Huang, Helen
    Mannel, Robert S.
    Homesley, Howard D.
    Fowler, Jeffrey
    Greer, Benjamin E.
    Boente, Matthew
    Birrer, Michael J.
    Liang, Sharon X.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (26): : 2473 - 2483
  • [6] Critical appraisal of bevacizumab in the treatment of ovarian cancer
    Yoshida, Hiroyuki
    Yabuno, Akira
    Fujiwara, Keiichi
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2351 - 2357
  • [7] IMPACT OF BEVACIZUMAB IN THE PRIMARY TREATMENT OF OVARIAN CANCER
    Matsumoto, T.
    Usami, T.
    Yasuoka, T.
    Inoue, A.
    Matsubara, Y.
    Fujioka, T.
    Matsubara, K. I.
    Sugiyama, T.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 763 - 763
  • [8] Ovarian Cancer: Bevacizumab as Adjuvant Treatment—Not Yet
    Amit Agarwal
    [J]. Indian Journal of Gynecologic Oncology, 2017, 15 (Suppl 1) : 9 - 10
  • [9] The roles and limitations of bevacizumab in the treatment of ovarian cancer
    Nakai, Hidekatsu
    Matsumura, Noriomi
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (07) : 1120 - 1126
  • [10] Bevacizumab treatment and quality of life in advanced ovarian cancer
    Canevari, Silvana
    Raspagliesi, Francesco
    Lorusso, Domenica
    [J]. FUTURE ONCOLOGY, 2013, 9 (07) : 951 - 954